<table>
<thead>
<tr>
<th>Disease Site &amp; Study #</th>
<th>Friday, January 20, 2023</th>
<th>Time*/Location</th>
</tr>
</thead>
</table>
| GI-Non-Colorectal       | **Title**: NRG/RTOG 1112: randomized phase III study of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC) (NCT01730937)  
**Presenter**: Laura A Dawson, MD  
**Abstract #**: 489 | Session Time: 4:30-6:00 PM  
Location: Level 3, Ballroom  
**Session B**: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract  
Time: 4:40-4:50 PM  
**Oral Presentation** |
| NRG/RTOG 1112          |                          |                |
| GI-Colorectal          | **Title**: Long-term results from NRG-GI002: A phase II clinical trial platform using total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC)  
**Presenter**: Thomas J. George, MD  
**Abstract #**: 7 | Session Time: 2:00 PM–3:30 PM  
Location: Level 3, Ballroom  
**Session C**: Cancers of the Colon, Rectum, and Anus  
Time: 2:42 PM-2:52 PM  
**Oral Presentation** |
| NRG-GI002              |                          |                |
| GI-Colorectal          | **Title**: Phase II/III study of circulating tumor DNA as a predictive biomarker in adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI004 (COBRA)  
**Presenter**: Van K. Morris, MD  
**Abstract #**: TPS259 | Session Time: 9:30 AM–10:55 AM  
Location: Level 1, West Hall  
**Trials in Progress Poster Session C**: Cancers of the Colon, Rectum, and Anus  
**Poster Presentation** |
| NRG-GI004              |                          |                |
| GI-Colorectal          | **Title**: NRG-GI005/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)  
**Presenter**: Michael Overman, MD  
**Abstract #**: TPS258 | Session Time: 9:30 AM–10:55 AM  
Location: Level 1, West Hall  
**Trials in Progress Poster Session C**: Cancers of the Colon, Rectum, and Anus  
**Poster Presentation** |
| NRG-GI005              |                          |                |
| GI-Colorectal          | **Title**: NRG-GI008: Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US)  
**Presenter**: Christopher Lieu, MD  
**Abstract #**: TPS260 | Session Time: 9:30 AM–10:55 AM  
Location: Level 1, West Hall  
**Trials in Progress Poster Session C**: Cancers of the Colon, Rectum, and Anus  
**Poster Presentation** |
| NRG-GI008              |                          |                |
| **Disease Site & Study #** | **The following presentation includes NRG author/investigators from an NSABP Foundation study** |                |
| GI-Colorectal          | **Title**: NSABP C-14: CORRECT-MRD II—Second colorectal cancer clinical validation study to predict recurrence using a circulating tumor DNA assay to detect minimal residual disease  
**Presenter**: Mohamed E. Salem, MD  
**Abstract #**: TPS284  
**NSABP Investigator**: Mohamed E. Salem, MD | Session Date/Time: Saturday, January 21, 2023, 9:30-10:55 AM  
Location: Level 1, West Hall  
**Trials in Progress Poster Session C**: Cancers of the Colon, Rectum, and Anus  
**Poster Presentation** |
| NSABP C-14             |                          |                |

* All times are EST